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A B S T R A C T   
Cellular senescence is a state of growth arrest that occurs after cells encounter various stresses. Senescence 
contributes to tumour suppression, embryonic development, and wound healing. It impacts on the pathology of 
various diseases by secreting inflammatory chemokines, immune modulators and other bioactive factors. These 
secretory biosignatures ultimately cause inflammation, tissue fibrosis, immunosenescence and many ageing- 
related diseases such as atrial fibrillation (AF). Because the molecular mechanisms underpinning AF develop-
ment remain unclear, current treatments are suboptimal and have serious side effects. In this review, we sum-
marize recent results describing the role of senescence in AF. We propose that senescence factors induce AF and 
have a causative role. Hence, targeting senescence and its secretory phenotype may attenuate AF.   
1. Atrial fibrillation 
Atrial fibrillation (AF) is the most common sustained cardiac 
arrhythmia, characterized by chaotic electrical impulses firing within 
the left atrium of the heart, which leads to irregular contraction with the 
left atrium. AF is detected clinically by palpating the pulse and the 
pulsation is classically described as irregularly irregular. AF was first 
recognised in 1749, but it was not until William Einthoven invented 
electrocardiography in the 20th century that AF was recorded on elec-
trocardiogram (ECG) (Lip and Beevers, 1995). 
Based on the Euro Heart Survey of more than 5000 AF patients 
(Kirchhof et al., 2016; Nieuwlaat et al., 2005), AF can be classified into 
four different categories: (i) first diagnosed, (ii) paroxysmal, (iii) 
persistent and (iv) permanent (Table 1). AF is an unusual condition that 
it can affect anyone but is more prevalent as we age (Chugh et al., 2014). 
Some sufferers are asymptomatic, some have few symptoms, and some 
experience symptoms so mild that even can’t notice the condition. On 
the other hand, some sufferers are highly symptomatic and short tran-
sient episode of atrial fibrillation, if frequent enough, can be highly 
debilitating. Even short transient episodes of AF can be very debilitating 
for these patients. It is unknown why patients range in the severity of 
their symptoms and others are asymptomatic. 
The most widely recognised complication of AF is the development 
of thrombus which is felt to originate within the left atrial appendage 
adjacent and connected to the left atrium (Chang et al., 2012). If a 
portion of the thrombus breaks away, referred to as an embolus, it makes 
its way into the circulation often finding its way into the cerebral cir-
culation resulting in a stroke. It is not uncommon for multiple emboli to 
pass into the brain causing multiple sites of injury in the brain. This 
explains why AF strokes tend to cause more debilitating strokes with 
higher rates of severe residual disability and higher mortality. While 
stroke prophylaxis tends to be the area most focused on in AF man-
agement, AF is frequently associated with heart failure. AF can be a 
complication of heart failure but can also in itself cause heart failure 
through poor control of the heart rate. The heart literally tires and the 
left ventricular function progressively declines, such that the patient 
develops a tachycardia induced cardiomyopathy leading to severe 
shortness of breathless and an inability to lie flat due to the sensation of 
smothering. 
Although AF has been known for a century with numerous associated 
studies, its mechanisms remain uncertain. Treatment of AF is hetero-
geneous as evidenced by the wide range of antiarrhythmic medications 
used in real world clinical practice. Some patients respond well to their 
antiarrhythmic medications whereas others derive little benefit, 
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suggesting that AF may have many different endotypes and mechanisms 
that require a personalised medicine approach. Effective identification 
of endotypes and mechanisms is needed to efficiently advance our un-
derstanding of the condition, supporting diagnosis and treatment, 
restoring normal sinus rhythm to reduce symptom burden and to pre-
vent complications. 
1.1. AF prevalence 
In 2020, AF affected 37.5 million patients worldwide, approximately 
0.51% of the global population (Lippi et al., 2020). The prevalence of AF 
is 1–2% which rises to around 10% by the time we reach 65 years of age. 
Detection of AF is believed to be growing rapidly as a result of the ageing 
population and greater accessibility to heart monitoring equipment and 
is largely opportunistic. From 1990–2010, the total number of AF pa-
tients increased 4%, while the number of new diagnoses increased 32%. 
During this period, the recorded death rate associated with AF increased 
94% (Chugh et al., 2014). 
More than 7.6 million adults aged over 65 were living with AF in the 
European Union in 2016, and it is believed that European AF patients 
will reach 17.9 million by 2060 (Lippi et al., 2020). In Northern Ireland 
the estimated number of known atrial fibrillation patients is approxi-
mately 40,000 and there will be many more unknown asymptomatic 
patients. 
1.2. Mechanism of atrial fibrillation 
Although there are several theories that could account for AF pro-
gression, the causative mechanisms of AF are still not clear. 
1.2.1. Ectopic firing theory 
In 1998, Haissaguerre reported that ectopic beats originating in the 
pulmonary veins spontaneously initiate AF and this is accepted as the 
prevailing hypothesis for AF genesis (Haissaguerre et al., 1998). AF 
initiation was mapped using multielectrode catheters to record the 
electrical activities proceeding AF and atrial ectopic beats and found 
that 94% of ectopic beats were in the pulmonary veins. Pulmonary veins 
contain pacemaker cells, transition and Purkinje cells together with the 
fibre structure and electrical characteristics making it suitable for 
initiating AF (Hocini et al., 2002; Perez-Lugones et al., 2003). Around 
62% AF patients showed no reoccurrence within 8 ± 6 months after the 
ectopic foci were ablated by radio-frequency treatment adding further 
support to this theory (Blaauw et al., 2002). 
However, this procedure known as Pulmonary Vein Isolation (PVI) 
had at best modest success out to five years and almost half of the pa-
tients required at least two procedures which has a 2.2% chance of 
serious complications meaning that better treatments and better patient 
selection is required (Guhl et al., 2016). The latter is challenging when 
the mechanisms remain unclear. 
1.2.2. AF re-entry 
The multiple-wavelet theory has been proposed for AF stabilisation. 
In this model, wavefront fractionation propagates through atria which 
results in self-perpetuating daughter-wavelets. Due to the differences in 
the atrial refractory period, mass and conduction velocity, the total 
wavelets number varies. As the wavelets accumulate, AF is stabilized 
and sustained (Cox et al., 1991; Fuster et al., 2006). 
It is further hypothesized that re-entrant rotors drive AF stabiliza-
tion. Wavelets break into daughter-wavelets when wavefronts encounter 
some obstacles such as scars and anisotropy. However, these daughter- 
wavelets form into rotors after they anchor the pulmonary veins and 
heterogeneous atrial tissues (Vaquero et al., 2008), which could induce 
disorganized waves to cause AF related chaotic atrial activation 
(Berenfeld et al., 2002). 
1.2.3. Atrial remodeling 
AF causes atrial remodeling, which in turn acts as a substrate to 
maintain, deepen and drive AF to a more permanent status. Atrial 
remodeling consists of electrical remodeling and structural remodeling. 
Electrical remodeling happens due to ion channel activity changes. In 
animal models, this remodeling happens within the first few hours of AF 
initiation. Electrical remodeling ultimately contributes to AF develop-
ment and maintenance (Corradi et al., 2008; Morillo et al., 1995; Wijf-
fels et al., 1995). 
Does electrical remodeling cause atrial remodeling or is it the other 
way around? We hypothesize that there may be an argument for 
senescence causing remodeling (discussed below in detail) which leads 
to AF which leads to progressive remodeling setting up a circle of left 
atrial modification. This supports the concept that atrial fibrillation 
begets atrial fibrillation. The precipitate to the initiating process may be 
increased left atrial pressure which most commonly arises from hyper-
tension. Atrial structure remodeling also show architectural changes 
such as increased tissue fibrosis and enlarged atria size (Corradi et al., 
2008) suggestive of atrial remodeling as a substrate for AF development. 
Further, morphological and functional changes post remodeling may 
ultimately contribute to development of persistent AF. 
1.3. Risk factors, clinical outcomes and treatments 
1.3.1. AF risk factors 
Numerous risk factors have been reported for AF. Among these, 
ageing is the most significant. AF prevalence is seven times higher in 
people aged from 65 to 69 years compared to people aged from 45 to 49 
years (Chugh et al., 2014). Sex was also a risk factor. Males have 
1.12-fold higher risk compared to females (Lippi et al., 2020). However, 
the AF mortality rate between males and females remains almost the 
same (Chugh et al., 2014). 
Cardiac conditions, including hypertension, previous heart failure 
and heart valve disease, are common risk factors. Diabetes (Kirchhof 
et al., 2016), together with factors such as smoking (Alonso et al., 2013), 
obesity (Wang et al., 2004), sedentary lifestyle (Alonso et al., 2013), 
heavy alcohol consumption (Kirchhof et al., 2016) and even excessive 
exercise, are accepted as non-cardiac causes. Apart from this, emerging 
studies show bacterial infection and virus infections such as SARS-CoV-2 
may also cause AF (Gawałko et al., 2020; Ichiki et al., 2009). 
1.3.2. Clinical features and treatments 
Many AF patients do not show symptoms in the early stage of AF. 
Those that do have symptoms vary in severity with some experiencing 
just one symptom such as palpitations, shortness of breath, or chest pain 
where as others may experience a combination of these (Rienstra et al., 
2012). As the disease changes from paroxysmal AF to permanent AF, 
patients may experience symptoms more frequently. Persistent and 
permanent AF are more likely to result in potential serious complica-
tions including stroke, thromboembolism, and heart failure. AF is much 
more likely to cause significant morbidity and can lead to a poor quality 
of life as opposed to mortality which is uncommon (Kirchhof et al., 
2016). The risk that AF patients will develop stroke is five-fold higher 
than non-AF individuals and it is estimated that about 20% of strokes are 
attributable to AF (Association, 2016). Around 12.5% of patients die in 
the first month after a stroke attack and 25% die within one year. For 
those who survive, 30% have recurrent strokes or transient ischaemic 
Table 1 
Classification, clinical feature and proportion of different types of AF.  
AF type Clinical feature Proportion 
First diagnosed First diagnosed, irrespective of duration and 
severity 
18.3% 
Paroxysmal AF Lasting 7 days or fewer 28.4% 
Persistent AF Rhythm control is achieved after 7 days 21.9% 
Permanent AF Sinus rhythm control is never established 29%  
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stroke and 50% have a disability (Association, 2016). Stroke is highly 
associated with ageing and the risk of stroke doubles every decade after 
the age of 55 (Association, 2016). Incidence of stroke in younger co-
horts, especially in black and south Asian young patients, are increasing 
due to consumption of cigarette, alcohol and illegal drugs (Association, 
2016). 
The current management of AF is multifaceted and includes heart 
rate control, cardioversion, catheter ablation, stroke and thromboem-
bolism prophylaxis. The mainstay of stroke prevention is anti-
coagulation using Warfarin but now includes Direct Oral Anticoagulants 
(DOACs) called Dabigatran, Rivaroxaban, Apixaban and more recently 
Edoxaban have taken over in many regions (Kirchhof et al., 2016). 
Anticoagulation drugs can prevent risk of stroke in 60% of AF patients 
(Hart et al., 2007), however only about half of AF patients are using 
these drugs according to stroke.org.uk. These treatments are accompa-
nied with side effects for example anticoagulation drugs will cause 
abnormal bleeding, cardioversion may increase the risk of heart failure 
and stroke. Further, catheter ablation could result in cardiac tamponade 
and pulmonary vein stenosis (in invasive therapies). None of these 
treatments are fully successful in curing AF, and indeed some cause AF 
relapse (Kirchhof et al., 2016; Rienstra et al., 2012). A better, detailed 
understanding of the molecular mechanisms of AF presents an oppor-
tunity to identify novel disease endotypes and more cost-effective tar-
geted therapeutics and enable patient stratification. 
2. Cellular senescence 
Cellular senescence is a state of stable and permanent growth arrest 
characterized by an inflammatory secretory phenotype (McCulloch 
et al., 2017; Rai and Adams, 2012; Van Deursen, 2014). In the 1960s, 
Leonard Hayflick found that human diploid cells cannot divide unlim-
itedly in vitro (being limited to approximately 50 ± 10 populations, 
known as “Hayflick Limit”) and this phenomenon was named cellular 
senescence (Hayflick, 1965). Since then, theoretical and experimental 
studies improved our understanding of this physiological process. 
Senescence can be triggered by various stresses such as activated on-
cogenes, oxidative stress, shortening of the telomere, DNA damage and 
insufficient supplementation (Campisi, 2005; Herbig and Sedivy, 2006; 
Ramirez et al., 2001). 
The onset of senescence is accompanied by changes in morphology, 
chromatin, transcriptome, metabolism and secretion (Herranz and Gil, 
2018). Senescent cells appear enlarged in size and flattened in shape in 
response to cytoskeletal protein changes (Cho et al., 2004; Wang and 
Gundersen, 1984). Each individual chromosome condenses to form 
heterochromatic structures, termed senescence-associated heterochro-
matin foci (SAHF) (Narita et al., 2003). Other senescent hallmarks 
include upregulation of p16INK4a and p21CIP1 and increased senescence- 
associated ß-galactosidase (SA-ß-Gal) activity (Caliò et al., 2015). It is 
thought that these changes help to maintain and deepen the senescence 
phenotype (Baker and Sedivy, 2013; Ivanov et al., 2013). 
2.1. Effects of senescence 
Senescent cells have both advantageous and detrimental effects. For 
example, senescence is a potent tumour suppression mechanism (Col-
lado and Serrano, 2010), helps in wound healing (Demaria et al., 2014; 
Jun and Lau, 2010) and is involved in embryonic development 
(Muñoz-Espín et al., 2013; Storer et al., 2013). Paradoxically, naturally 
occurring senescent cells have been shown to contribute to tumour 
progression and organ dysfunction in the kidney and heart (McHugh and 
Gil, 2018). Long term senescence has deleterious effects by shortening 
lifespan (Baker et al., 2016; Muñoz-Espín et al., 2013; Storer et al., 
2013), and contributing to ageing and ageing-associated diseases (Baker 
et al., 2008, 2011) (see Table 2 and Fig. 1). In aged rodent models, 
accumulation of senescent cells characterized by upregulation of p16 
and p21 indicated a possible correlation between senescence and ageing 
Table 2 
Senescence biomarkers identified in various diseases.  
Detrimental impact of cellular senescence 
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et al., 2015), type 2 










Eye diseases Cataracts (Fu et al., 
2016), glaucomatous 
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(Hudgins et al., 2018). Inactivation of p16 has been demonstrated to 
delay onset of age-related symptoms in sarcopenia, coronary artery 
disease (CAD) and osteoarthritis (Baker et al., 2008; Bussian et al., 2018; 
Sousa-Victor et al., 2014). Hutchinson-Gilford Progeria Syndrome 
(HGPS) is associated with premature senescence regulated by telomere 
dysfunction and DNA-damage signalling (Benson et al., 2010). Drugs 
that target senescent cells extend mice healthspan, lifespan and delay 
the onset of organ dysfunction without any notable side effects (Baker 
et al., 2016, 2011; Xu et al., 2018). Cellular senescence is therefore a 
well-known contributor to ageing and ageing related diseases. 
2.2. Senescence-associated secretory phenotype (SASP) 
Ongoing senescence results in continued secretion of bioactive 
molecules that may ultimately end up in the blood. Such molecules are 
called the senescence-associated secretory phenotype (SASP) (Campisi 
and Di Fagagna, 2007; Campisi, 2005; Coppé et al., 2010). SASP was 
first reported by Judith Campisi, when inducing senescence in fibro-
blasts and epithelial cells by genotoxic stress. They found that inflam-
matory cytokines, growth factors, immune modulators and malignancy 
associate factors increased in vitro (Coppé et al., 2008). The same 
phenotype was observed in vivo in patients receiving chemotherapy 
(Taschner-Mandl et al., 2016). Interestingly, SASP can both be beneficial 
and harmful to the organism. It is reported to be involved in wound 
healing and immune cell recruitment to eliminate senescent cells 
(Demaria et al., 2014; Velarde and Demaria, 2016). Age related accu-
mulation of senescent cells and associated secretory molecules can cause 
Table 2 (continued ) 
Detrimental impact of cellular senescence 
Diseases Disease sub-types Senescence 
biomarker 
Disease model 
López-Luppo et al., 
2017) 
Genetic disorder Down syndrome ( 
Nawa et al., 2019), 
Hutchinson-Gilford 
Progeria syndrome ( 








Liver diseases Hepatocellular 
carcinoma (Paradis 
et al., 2001), liver 
cirrhosis ( 
Krizhanovsky et al., 
2008), non-alcoholic 
liver fatty diseases ( 
Zhang et al., 2012), 
non-alcoholic 
steatohepatitis ( 
Tomita et al., 2012) 
SA-ß-Gal, Ki- 
67, p53, p21, 
p16 
Liver tissue, mice  
Fig. 1. Age associated diseases where senescence has been causally implicated. 37 senescence-associated diseases are classified into 9 major categories: neurode-
generative diseases, lung diseases, liver diseases, metabolic diseases, musculoskeletal diseases, eye diseases, cardiovascular diseases, renal diseases and ge-
netic disorders. 
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immunosenescence, organ and tissue dysfunction (Weiskopf et al., 
2009). SASP can have pathological consequences that can cause chronic 
diseases such as osteoarthritis and atherosclerosis (Matthews et al., 
2006; Price et al., 2002). Furthermore, SASP is implicated in the 
development of tumours by affecting the neighbouring cells in papillary 
thyroid carcinoma invasions (Kim et al., 2017b). A SASP atlas contain-
ing soluble and exosome SASP factors has recently been established, in 
which proteomic analysis was performed for quiescent and replicative 
fibroblasts and epithelial cells induced by multiple triggers. Among the 
proteins analysed, growth differentiation factor-15 (GDF-15) and matrix 
metallopeptidases (MMPs) were identified as the core SASP proteins 
(Basisty et al., 2020). Interestingly, GDF15 has also been found to be a 
human ageing biomarker, identified by comparing the plasma proteome 
of individuals ranging from 18 to 95 years (Basisty et al., 2020; Lehallier 
et al., 2019). Although the precise role of GDF-15 is still not known, it 
may be a potential target for not only drug development but also aged 
disease risk prediction (Velarde et al., 2013; Wollert et al., 2017). 
Senescence is significantly correlated with ageing and ageing-related 
diseases and SASP may have the potential to predict risk and serve as 
a target for ageing-related diseases. 
3. Interaction between atrial fibrillation and senescence 
Since AF was discovered a century ago, significant efforts have been 
made to define it. In spite of this the precise mechanism is still unknown, 
with structural remodeling (Burstein and Nattel, 2008), electric 
remodeling (Allessie et al., 2001), autonomic remodeling (Chou and 
Chen, 2009) and other theories suggested to explain the aetiology of AF. 
Atrial fibrosis and atrial enlargement have been reported to cause atrial 
structure remodeling and are regarded as the basis of AF development 
and maintenance (Glukhov et al., 2015). Recently, AF was identified as 
closely correlated with senescence and emerging studies indicate that 
senescence plays a key role. For example, senescence triggers and me-
diators including oxidative stress, excessive reactive oxygen species 
(ROS), shortened telomere and mitochondria damage have been shown 
to contribute to AF progression (Lin et al., 2003; Sovari and Dudley, 
2010). Furthermore, mitochondrial DNA mutations and injury caused by 
oxidative stress were found to be increased in AF patients (Lin et al., 
2003). Analysis of blood samples from AF patients and those in normal 
sinus rhythm showed that AF patients have shorter telomeres (Carlquist 
et al., 2016). However, it is not known whether cells in the heart can 
cause telomere shortening in blood cells, or indeed if this is linked to the 
ageing process in general. The human heart contains a variety of cell 
types such as cardiac fibroblasts, cardiomyocytes and macrophages 
(Tucker et al., 2020). Cardiomyocytes do not divide, and the level of 
DNA damage might be low when compared to rapidly dividing cells in 
the circulatory system. However, they undergo ongoing transcription 
that results in chromatin remodeling, potentially causing DNA damage. 
Similarly, free radicals generated during normal physiological processes 
might also cause DNA damage. Finally, ongoing contraction and relax-
ation over decades produces mechanical stress that might trigger DNA 
damage. 
Translational expression profiling of atrial appendages from parox-
ysmal/persistent AF patients (aged from 58 to 82 years old) and sinus 
rhythm cohorts (aged from 57 to 79 years old) has shown senescence 
biomarkers and prothrombotic and proinflammatory factors were 
elevated in AF patients compared to a sinus rhythm group (Jesel et al., 
2020). These biomarkers included an increased abundances of tumour 
suppressor proteins p53 and p16, tissue factor, MMP-9 and decreased 
endothelial nitric oxide synthase (eNOS) (Matsushita et al., 2001). 
Interestingly, there is a positive correlation of p53 and p16 with the 
severity of AF, indicating these biomarkers increased as AF deepened 
from sinus rhythm to paroxysmal AF and persistent AF. However, eNOS 
was down regulated gradually, providing evidence that senescence is 
pathologically involved in AF (Jesel et al., 2020). Taken together, these 
results show that senescence may be involved in AF initiation and/or 
development. 
3.1. Potential mechanism of senescence-induced atrial fibrillation (SIAF) 
Atrial fibrosis, which is a feature of atrial structure remodeling is 
implicated in AF development and maintenance (Dzeshka et al., 2015; 
Lau et al., 2016; Spach and Boineau, 1997). Atrial fibrosis is charac-
terized by cardiac fibroblast proliferation, excessive myofibroblast dif-
ferentiation and increased extracellular matrix (ECM) production of 
collagen, which terminally affects the functions of myocardium (Plato-
nov, 2017). In animal models, induction of atrial interstitial fibrosis by 
congestive heart failure increased the risk of developing AF (Li et al., 
1999). In human subjects, a higher level of atrial fibrosis has been 
observed in AF patients than in sinus rhythm groups through biopsy and 
autopsy data (Everett IV and Olgin, 2007; Kostin et al., 2002). 
Furthermore, atrial fibrosis was observed in subjects who developed AF 
after coronary bypass surgery but not in non-AF patients (Mariscalco 
et al., 2006). It is hypothesized that senescence is involved in atrial 
fibrosis-induced AF (Batlle et al., 2015). By analysing atrial appendage 
samples of AF patients and sinus rhythm individuals, higher atrial 
fibrosis levels and shortened telomeres were observed in AF patient 
groups, implicating senescence in the process of atrial fibrosis and AF 
(Batlle et al., 2015). Renin-angiotensin system, angiotensin converting 
enzyme (ACE) (Iravanian and Dudley Jr, 2008), visceral adipose tissue 
(Abe et al., 2018), TGF-ß (Verheule et al., 2004), pro-inflammatory cy-
tokines (Marcus et al., 2010), ECM such as collagen (Levi et al., 2020), 
matrix metalloproteinases (MMPs) (Li et al., 2000), connexin 43 (Thi-
bodeau et al., 2010), mitochondrial and oxidative stress (Xie et al., 
2015) are implicated in AF associated fibrosis. Interestingly, many of 
these proteins are also hallmarks of senescence (Lau et al., 2016; Luo 
et al., 2007; Sawaki et al., 2018). SASP has also been shown to be 
involved in fibrosis induction by promoting inflammation and disrupt-
ing tissues (Muñoz-Espín et al., 2013; Van Deursen, 2014). These results 
suggest understanding atrial fibrosis may be important in clarifying the 
role of senescence in AF (Fig. 2). 
3.1.1. The role of extracellular matrix in senescence-induced atrial 
fibrillation 
ECM comprises collagens, glycoproteins, MMPs and other ECM- 
associated proteins. The role of ECM is to provide a structural scaffold 
for cell proliferation, cell communication and to mediate signal trans-
duction in organ and tissue interstitial matrix (Choi et al., 2011; Levi 
et al., 2020). ECM is associated with tissue fibrosis, development, wound 
healing, cancer progression (Ghosh et al., 2020) and heart diseases 
(Reese-Petersen et al., 2020). In particular, atrial fibrosis is known to be 
caused by deposition of excessive ECM. Elevated expression of collagens, 
MMPs, fibronectin with other ECM-associated proteins contribute to 
ECM-associated atrial fibrosis (Levi et al., 2020). It is possible that in the 
ageing heart, senescent cells secrete SASP, some of which are also part of 
ECM proteins including MMPs, indicating there is a crosstalk between 
senescence and ECM components. ECM properties and specific protein 
expression levels change when cells enter a senescent state, for example 
increasing insolubility and up-regulating collagens and fibronectins 
(Colige et al., 1992; Sell and Monnier, 1989). Mice engineered to express 
collagenase-resistant type I collagen have a senescent phenotype leading 
to shortened lifespan (Vafaie et al., 2014). ECM proteomic analysis 
comparing human senescent and young diploid fibroblasts found that 
several ECM proteins were differentially expressed in senescent cells 
(Yang et al., 2011). These studies indicate ECM may contribute to atrial 
fibrosis through expression of proteins such as collagen 1 and MMPs. 
3.1.2. Role of Angiotensin II (Ang II) and TGF-ß/Smad in senescence- 
induced atrial fibrillation 
Inflammation is one of the main drivers of atrial fibrosis. Senescent 
cells secrete interleukins and MMPs that contribute to inflammation 
(Rodier et al., 2009). These inflammatory markers mediate tissue 
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fibrosis by activating the TGF-ß pathway (Lee et al., 2001). TGF-ß is 
known to induce senescence in hepatocellular carcinoma cells (Senturk 
et al., 2010) and bone marrow mesenchymal stem cells (Wu et al., 
2014). TGF-ß also contributes to ageing-related disorders such as Alz-
heimer’s disease and muscle atrophy by causing inflammation, tissue 
fibrosis and metabolic dysfunction (Tominaga and Suzuki, 2019). In 
cardiac cells and in AF mouse models, a high level of TGF-ß was 
accompanied with prolonged AF duration, increased tissue fibrosis, 
collagenous fibers, collagen synthesis and fibrotic effect associated 
H-proline (Li et al., 2019). Further studies in aged hearts show that 
fibrosis was caused by TGF-ß dependent modulation of Nanog. Nanog 
regulates collagen synthesis and monocyte chemoattractant protein-1 
(MCP-1) transiting monocytes into myeloid fibroblasts which increase 
fibrosis (Cieslik et al., 2014). The TGF-ß pathway is implicated in the 
induction of atrial fibrosis, possibly through stem cell factors such as 
Nanog. 
Ang II, a well-known profibrotic factor, plays a significant role in 
cardiac inflammation, fibroblast proliferation, cardiac contractility and 
finally cardiac structure remodeling through atrial fibrosis (He et al., 
2011; Kim et al., 2017a). In a study investigating the potential mecha-
nism of how Ang II exhibits its role on inflammation, HL-1 atrial cells 
were treated with Ang II. By transcriptional and translational analysis, it 
was shown that Ang II increased inflammation associated proteins and 
pathways such as TNFα, TGF-ß, NF-κB, ILs, ROS, cellular calcium and the 
MAPK/JNK pathway. Ang II type 1 receptor (AT1R), which is involved 
in vascular remodeling, was found to be upregulated by Ang II treat-
ment. Whether AT1R could induce atrial inflammation still remains 
unclear. Addition of AT1R blocker to an atrial cell line decreased the 
inflammatory markers including ILs, JNK phosphorylation level, ROS, 
TGF-ß and NF- κB. This indicates atrial inflammation could be inhibited 
by targeting Ang II. In AF patients’ samples, the levels of Ang II were 
found to correlate with inflammation (Kim et al., 2017a). In a rabbit 
model of AF, Ang II, AT1R, TGF-ß and Smads were found to correlate 
with atrial fibrosis (He et al., 2011). Ang II induces cellular senescence in 
vascular smooth muscle cells (VSMCs) by regulating p53 and p21, whilst 
concomitantly increasing inflammation. However, inhibiting the 
senescence pathway through inhibition of p53/p21 significantly 
reduced inflammation and atherosclerosis (Kunieda et al., 2006). 
Fig. 2. Signal transduction of senescence-induced atrial fibrosis and potential diagnosis and treatment targets. Heart tissue encountering ageing, telomere attrition, 
oxidative stress, mitochondrial DNA injury and mechanical stress undergoes senescence. Collagens, Nanog, ILs, MMPs, MCP-1, ACE and Ang II are upregulated by 
thrombin and Ang II/TGF-ß pathways, which finally results in atrial fibrosis induced AF. Specific SASP factors may be exploited to develop novel AF risk prediction 
algorithms. Targeting senescent cardiac cells and their SASP using senolytic compounds, immune cells, CAR T cells and sEVs may attenuate AF. 
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Atrial endothelial cells (AECs) from porcine atria display senescence 
hallmarks when passaged in cell culture. AECs have increased SA-ß-Gal 
activity, p53, p16 and p21 showing AECs were entering senescence 
(Hasan et al., 2018). Atrial fibrosis remodeling and inflammation was 
detected by MMPs, TGF-ß and by measuring local Ang II levels along 
with AT1R. These results indicated that atrial endothelial cellular 
senescence contributed to atrial inflammation, fibrosis and atrial 
remodeling possibly via Ang II/AT1R and TGF-ß (Hasan et al., 2018). 
Clinical AF samples showed that increased senescence markers were 
significantly associated with overexpressed collagenase I/III and TGF-ß, 
indicating senescence may induce atrial fibrosis (Xie et al., 2017). Ang II 
may contribute to AF by inducing senescence and mediating atrial 
fibrosis. Targeting Ang II and its receptor AT1R may therefore be 
attractive therapeutic option for the treatment of senescence mediated 
AF. 
3.1.3. Role of thrombin in senescence-induced atrial fibrillation 
AF is closely associated with a hypercoagulation state that causes 
stroke by forming blood clots. Blood coagulation, in turn, could 
contribute to AF progression (Spronk et al., 2017). Thrombin is widely 
known to play a key role in thrombogenesis, clot formation, which 
contributes to atrial fibrosis, atrial remodeling, and affects left atria 
electrical signalling together with the mechanical characteristics that 
finally result in AF (Chang et al., 2012; Jumeau et al., 2016; Spronk 
et al., 2017). It affects a variety of cells in the heart including car-
diomyocytes, fibroblasts, endothelial cells and vascular smooth muscle 
cells. As a consequence of thrombin stimuli, protease-activated receptors 
(PARs) are activated, consisting of 4 members and belonging to the 
G-protein-coupled receptors (Jacques et al., 2000). The thrombin-PAR 
signalling pathway is involved in liver- (Foglia et al., 2019), lung-(Ma-
dala et al., 2012) and heart-tissue fibrosis (Walsh, 2006), inflammation, 
cancer, embryonic development and especially in cardiovascular dis-
eases (Martorell et al., 2008). In isolated rat atrial fibroblasts, thrombin 
treatment increased phosphorylation of the PAR signal pathway proteins 
Akt, Erk and p38 and of the inflammatory markers IL-6, MCP-1 and 
MMPs (Hasan et al., 2019). These proteins are linked to senescence and 
promoters of atrial fibrosis, indicating that thrombin regulates senes-
cence and fibrotic diseases. Cells treated by PAR1 agonist showed an 
increase of thrombin, TGF-ß, MCP-1 and H-proline (Lim et al., 2013). In 
mouse models of AF, levels of thrombin are increased post AF onset (Lim 
et al., 2013; Spronk et al., 2017). Atrial endothelial cells treated with 
thrombin in vitro were found to upregulate senescence markers such as 
ROS, SA-ß-gal activity, p53, p21 and p16 (Hasan et al., 2019). As a result 
of atrial endothelial cellular senescence, pro-fibrotic and 
pro-remodeling patterns emerge, which are common manifestations of 
AF. Results from a rat model showed that both atrial remodeling and AF 
episodes were improved by injecting direct thrombin inhibitors, quite 
possibly by targeting senescence hallmarks (Jumeau et al., 2016). 
Interestingly, during the thrombin induced senescence, two angiotensin 
related proteins, ACE and AT1R increase (Hasan et al., 2019). Thrombin 
induced senescence could be significantly inhibited by treating endo-
thelial cells with losartan and perindoprilat, which is an AT1R antago-
nist and an ACE inhibitor, respectively (Hasan et al., 2019). These 
studies show that thrombin contributes to senescence and atrial fibrosis 
which initiates and/or maintains AF. Hence, thrombin could be a future 
therapeutic target for AF (Spronk et al., 2017). 
3.2. Clearing senescent cells as a therapy for atrial fibrillation 
It is hypothesized that clearing senescent cells may ameliorate many 
age associated conditions (Childs et al., 2015). Senescent cells are 
sometimes referred to as “Zombie cells” that resist apoptosis induced 
death by upregulating anti-apoptotic proteins such as Mcl1 (Demelash 
et al., 2015; Dikovskaya et al., 2015) and BCL-2 (Chang et al., 2016). 
Senescent cells can be effectively removed by pharmacological and 
genetically engineered strategies. Senolytic compounds (Chang et al., 
2016), senolytic immune cells (Pereira et al., 2019), engineered immune 
cells (Amor et al., 2020), and small extracellular vesicles from young 
subject fibroblasts (Fafián-Labora et al., 2020) eliminated senescent 
cells effectively and delayed senescence-associated diseases (Bussian 
et al., 2018). These strategies have been very successful in cellular and 
murine models and have shown their effectiveness in attenuating 
senescence-associated symptoms (Bussian et al., 2018). No treatments 
have been shown to improve AF, but we suggest that there is great po-
tential in senolytics as the role of senescence in pathogeneses of AF 
becomes clearer. 
Senolytic compounds are a class of compounds, antibodies and 
peptides that preferentially eliminate senescent cells by targeting anti- 
apoptotic molecules such as BCL-2 and BCL-xL (Chang et al., 2016). 
The combination of Dasatinib and Quercetin (D & Q) was the first re-
ported senolytic used for eliminating senescent cells. Both D & Q are 
anti-cancer drugs, and each used alone is not effective enough to clear 
senescent cells. Interestingly, the combination of D & Q showed a wide 
killing spectrum in senescent preadipocytes and human umbilical vein 
endothelial cells (HUVECs), which finally improved osteoporosis (Farr 
et al., 2017), hepatic steatosis, pulmonary fibrosis, cardiovascular dis-
eases (Kim and Kim, 2019; Song et al., 2020) and prolonged lifespan in 
old mice (Xu et al., 2018). Inspired by the usage of D & Q, research has 
focussed on small molecule-compound screening for potential seno-
therapy. ABT-263 (Chang et al., 2016), ABT-737 (Yosef et al., 2016), 
FOXO4-DRI peptide (Baar et al., 2017), fiesten (Zhu et al., 2017), car-
diac glycosides (CGs) (Guerrero et al., 2019; Triana-Martínez et al., 
2019) and others have been reported to have broad senolytic activity. 
Based on the effects of these senolytic compounds, clinical trials have 
been initiated to investigate whether the activity is consistent in pa-
tients. First in human studies have shown that combinations of D & Q 
improved symptoms of idiopathic pulmonary fibrosis (Hickson et al., 
2019). Data from ClinicalTrials.gov shows there are several senolytic 
compounds under clinical trials: D & Q targeting Alzheimer 
(NCT04063124), Chronic kidney disease (NCT02848131), skeletal 
health (combined with fisetin, NCT04313634) and fisetin targeting 
osteoarthritis-related articular cartilage degeneration (NCT04210986). 
For AF, a potential senotherapy might target senescent cardiac cells. 
Although there hasn’t been such a specific senolytic compound for AF 
treatment, digoxin, currently used for AF treatment to control irregular 
heartbeat, was reported to have a senolytic activity (Guerrero et al., 
2019; Triana-Martínez et al., 2019). 
Senescence can also occur in various types of immune cells referred 
to as immunosenescence, which decreases immune cell numbers and 
weakens immune responses to infections (Aiello et al., 2019; Pereira 
et al., 2019). Senescent dermal fibroblast secreted SASP induces HLA-E 
that inhibits NK cells and CD8+ T cells. Blocking the interaction between 
HLA-E and senescent cells activates NK cells and CD8+ T cells to perform 
senolytic activity (Pereira et al., 2019). In murine liver, NK cells also 
recruit macrophages and neutrophils for senescence clearance (Xue 
et al., 2007). CD4+ T cells, facilitated by macrophages, kill Nras-induced 
pre-malignant senescent hepatocytes (Kang et al., 2011). Senescent cells 
overexpress surface protein urokinase-type plasminogen activator re-
ceptor (uPAR). Chimeric antigen receptor (CAR) T cells preferentially 
kill uPAR-expressing senescent cells, an approach that may well be used 
in humans (Amor et al., 2020). Small extracellular vesicles (sEVs) from 
young subjects’ fibroblasts have senolytic activity. Cells from old in-
dividuals showed decreased levels of senescent markers in response to 
treatment with sEVs and this effect has proved consistent in a mouse 
model (Fafián-Labora et al., 2020). This method represents a potential 
new therapeutic strategy to improve senescence-associated pathologies. 
4. Conclusions 
AF, as a chronic disease, is significantly correlated with ageing. 
Cellular senescence, one of the well-known contributors to the ageing 
process is believed to contribute to AF development by regulating ECM, 
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ANG II, TGF-ß, thrombin and other signalling pathways. Targeting these 
signalling pathways by means of specific senolytic compounds, immune 
cells, CAR T cells and sEVs that preferentially eliminate senescent cells 
may be a potential treatment for AF. 
5. Perspectives 
AF poses heavy economic, healthcare and social burdens as a result 
of high death rates and a low quality of life. In the western European 
countries, AF cost €660 m (Germany) to €3200 m (Italy) every year 
(Velleca et al., 2019). Further complications, secondary to AF, such as 
stroke, cost the European Union another €45bn annually (Velleca et al., 
2019). Precise identification of AF mechanisms and better subclassifi-
cation of molecular endotypes will create opportunities for better di-
agnostics, therapies and biomarker development that can significantly 
reduce the economic burden of the condition and extend human life-
span. The current gold standard method for AF diagnosis is ECG. How-
ever, ECG can not determine the self-terminated AF types that have the 
potential to develop into persistent AF (Matusik et al., 2019). New 
methods are needed to improve not only the diagnosis methods but also 
to improve the clinical care pathway. One way that could be effective for 
better diagnosis is combining the senescence markers with ECG, imaging 
and clinical measurements. For example, there is already research 
focused on stroke and embolism risk prediction using a particular SASP 
factor GDF-15 along with NT‑proBNP (Matusik et al., 2019). High levels 
of GDF-15 are also associated with atheroslerotic CVD, heart failure, and 
all-cause mortality (Ho et al., 2018). Further, high-throughput screening 
of novel senolytic compounds, specific immune cells and engineered T 
cells that target senescent cardiac cells, and possibily sEVs could lead to 
development of potential treatments (Amor et al., 2020; Chang et al., 
2016; Fafián-Labora et al., 2020; Pereira et al., 2019). It is still not 
certain that the beneficial effects are indeed due to the effective killing 
of senescent cells (Hickson et al., 2019) or what exact cardiac cell types 
could be targets of senolytics. 
During the current global pandemic caused by SARS-CoV-2, coro-
navirus diseases 2019 (COVID-19) has posed emerging treatments and 
caring difficulties in AF patients. COVID-19 is reported to be associated 
with arrhythmia, of which AF is the most frequent. Concomitant treat-
ments for COVID-19 patients and cancer patients may introduce car-
diotoxicity to cause/worsen AF (Gatti et al., 2020). Besides, SARS-CoV-2 
infection may contribute to senescence accumulation by secreting 
proinflammatory cytokines and chemokines (Nehme et al., 2020), which 
in turn weakens immune system in response to SARS-CoV-2 infection. To 
conclude, even though the field of senescence and AF is still emerging, it 
has huge economic, societal and scientific potential in the coming years. 
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Desprez, P.-Y., Campisi, J., 2008. Senescence-associated secretory phenotypes reveal 
cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS 
Biol. 6, 2853–2868. 
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